Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 5/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770510 | 0.91 | VEGFA (0.55) | VEGFAEGLN1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL17005958 | 0.91 | VEGFA (0.59) | VEGFAEGLN1CYP2D6TSHRALDH1A1 | |
| SCHEMBL12598810 | 0.90 | VEGFA (0.72) | VEGFAEGLN1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL17005837 | 0.89 | VEGFA (0.57) | VEGFAEGLN1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL17005979 | 0.88 | VEGFA (0.56) | VEGFAEGLN1ALDH1A1KDM4EHTT | |
| SCHEMBL17005972 | 0.88 | VEGFA (0.56) | VEGFAEGLN1ALDH1A1KDM4EHTT | |
| SCHEMBL17005911 | 0.88 | VEGFA (0.56) | VEGFAEGLN1CYP2D6ALDH1A1KDM4E | |
| SCHEMBL1770053 | 0.88 | EGLN1 (0.64) | VEGFAEGLN1FAAHKMT2AMEN1 | |
| SCHEMBL1770508 | 0.88 | VEGFA (0.64) | VEGFAEGLN1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL1770477 | 0.88 | VEGFA (0.66) | VEGFAEGLN1ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2853265-B1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | claimed |
| EP-2496084-B1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS INC (US) | 2015-06-10 | — | — | EP | claimed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | claimed |
| EP-2853265-A1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | Aerpio Therapeutics Inc. (US) | 2015-04-01 | — | — | EP | claimed |
| EP-2649998-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | claimed |
| EP-2649998-A1 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | claimed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | claimed |
| EP-2496236-B1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2013-05-01 | — | — | EP | claimed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | claimed |
| EP-2496236-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| EP-2496084-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | claimed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | claimed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | claimed |
| WO-2011057115-A1 | PROLYL HYDROXYLASE INHIBITORS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | claimed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| CN-106232120-B | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2- (1H) -ones | 爱尔皮奥治疗有限公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3698794-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3107542-B1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| EP-2853265-B1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2853265-B1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3107542-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | Aerpio Therapeutics, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-2496082-B1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2496082-B1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9388135-B2 | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones | AERPIO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2954899-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2954899-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2952192-A1 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015126860-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150218098-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150218098-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150218098-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
| EP-2496084-B1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2496084-B1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2853265-A1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | Aerpio Therapeutics Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| EP-2649998-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | disclosed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | disclosed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | disclosed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2649998-A1 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2496236-B1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2496236-B1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2496082-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2496084-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2496236-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057115-A1 | PROLYL HYDROXYLASE INHIBITORS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057115-A1 | PROLYL HYDROXYLASE INHIBITORS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CYP2D6 3157/4885 |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885CYP2D6 4758/4885 |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | ALPI, SI, SLC10A2 | VEGFA 4546/4885EGLN1 2861/4885CYP2D6 1945/4885 |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CYP2D6 3157/4885 |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | CYP4B1, CYP8B1, HPD | VEGFA 4681/4885EGLN1 102/4885CYP2D6 152/4885 |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CYP2D6 3157/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CYP2D6 3157/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885CYP2D6 4758/4885 |
| US-20150218098-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CYP2D6 3157/4885 |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885CYP2D6 4758/4885 |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885CYP2D6 4758/4885 |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CYP2D6 3157/4885 |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885CYP2D6 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.